Journal
NEUROMOLECULAR MEDICINE
Volume 23, Issue 1, Pages 86-98Publisher
HUMANA PRESS INC
DOI: 10.1007/s12017-020-08629-9
Keywords
PPAR delta; Agonists; Lipid metabolism; Neurodegenerative disorders; Neuroprotection; Hypoxia; ischemia; Alzheimer' s disease
Categories
Funding
- National Science Centre Grant [2019/35/N/NZ4/03706]
Ask authors/readers for more resources
PPAR-beta/delta is a nuclear receptor involved in lipid metabolism and cellular functions, playing a potential role in inflammation and disease treatment. Its role in neurodegeneration and neuroinflammation remains poorly understood, despite potential therapeutic applications in neurological disorders.
Peroxisome proliferator-activated receptor (PPAR) beta/delta belongs to the family of hormone and lipid-activated nuclear receptors, which are involved in metabolism of long-chain fatty acids, cholesterol, and sphingolipids. Similar to PPAR-alpha and PPAR-gamma, PPAR-beta/delta also acts as a transcription factor activated by dietary lipids and endogenous ligands, such as long-chain saturated and polyunsaturated fatty acids, and selected lipid metabolic products, such as eicosanoids, leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Together with other PPARs, PPAR-beta/delta displays transcriptional activity through interaction with retinoid X receptor (RXR). In general, PPARs have been shown to regulate cell differentiation, proliferation, and development and significantly modulate glucose, lipid metabolism, mitochondrial function, and biogenesis. PPAR-beta/delta appears to play a special role in inflammatory processes and due to its proangiogenic and anti-/pro-carcinogenic properties, this receptor has been considered as a therapeutic target for treating metabolic syndrome, dyslipidemia, carcinogenesis, and diabetes. Until now, most studies were carried out in the peripheral organs, and despite of its presence in brain cells and in different brain regions, its role in neurodegeneration and neuroinflammation remains poorly understood. This review is intended to describe recent insights on the impact of PPAR-beta/delta and its novel agonists on neuroinflammation and neurodegenerative disorders, including Alzheimer's and Parkinson's, Huntington's diseases, multiple sclerosis, stroke, and traumatic injury. An important goal is to obtain new insights to better understand the dietary and pharmacological regulations of PPAR-beta/delta and to find promising therapeutic strategies that could mitigate these neurological disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available